judith delage

Dr. judith delage

Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
judith delagejudith delage
judith delage
AFAlain Faivre-Chauvet
Alain Faivre-Chauvet
JBJacques Barbet
Jacques Barbet
JFJulie Katrin Fierle
Julie Katrin Fierle
NSNiklaus Schaefer
Niklaus Schaefer
John PriorJohn Prior
John Prior
1C1m-Fc, an anti-tumor endothelial marker 1 (TEM-1) scFv-Fc fusion protein antibody, was previously successfully radiolabeled with 177Lu. TEM-1 specific tumor uptake was observed together with a non-saturation dependent liver uptake that could be related to the number of dodecane tetraacetic acid (DOTA) chelator per 1C1m-Fc. The objective of this study was to verify this hypothesis and to find the best DOTA per 1C1m-Fc ratio for theranostic applications. 1C1m-Fc was conjugated with six concentrations of DOTA. High-pressure liquid chromatography, mass spectrometry, immunoreactivity assessment, and biodistribution studies in mice bearing TEM-1 positive tumors were performed. A multi-compartment pharmacokinetic model was used to fit the data and a global pharmacokinetic model was developed to illustrate the effect of liver capture and immunoreactivity loss. Organ absorbed doses in mice were calculated from biodistribution results. A loss of immunoreactivity was observed with the highest DOTA per 1C1m-Fc ratio. Except for the spleen and bone, an increase of DOTA per 1C1m-Fc ratio resulted in an increase of liver uptake and absorbed dose and a decrease of uptake in tumor and other tissues. Pharmacokinetic models correlated these results. The number of DOTA per antibody played a determining role in tumor targeting. One DOTA per 1C1m-Fc gave the best pharmacokinetic behavior for a future translation of [177Lu]Lu-1C1m-Fc in patients.

7 September 2023 in Journal of Labelled Compounds and Radiopharmaceuticals
Verified
Journal Article
Open access
JCJulien Costes
Julien Costes
KCKilian Casasagrande
Kilian Casasagrande
CDConstance Dubegny
Constance Dubegny
JCJuan Castillo
Juan Castillo
JKJens Kaufman
Jens Kaufman
judith delagejudith delage
judith delage
[68Ga]Ga‐PentixaFor is a frequently used radiotracer to image the CXCR4/CXCL12 axis in various malignancies, infections, and cardiovascular diseases. To answer increasing clinical needs, an automatized synthesis process ensuring efficient and reproducible production and improving operator's radioprotection is needed. [68Ga]Ga‐PentixaFor synthesis has been described on other synthesizers but not on the miniAiO. In this work, we defined automated synthesis process and an analytical method for the quality control of [68Ga]Ga‐PentixaFor. Validation batches were performed under aseptic conditions in a class A hotcell. All the quality controls required by the European Pharmacopea (Eur. Ph) were performed. The analytical methods were validated according to the International Conference Harmonization (ICH) recommendations. Validation batches were performed with a radiochemical yield of 94.8 ± 2.6%. All the quality controls were in conformity with the Eur. Ph, and the validation of the analytical method complied with the ICH. The environmental monitoring performed during the synthesis process showed that the aseptic conditions were ensured. [68Ga]Ga‐PentixaFor was successfully synthesized with the miniAiO by a fully automated process. This robust production mode and the quality control have been validated in this study allowing to increase the access of patients to this new promising radiopharmaceutical.

25 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
judith delagejudith delage
judith delage
SGSilvano Gnesin
Silvano Gnesin
John PriorJohn Prior
John Prior
JBJacques Barbet
Jacques Barbet
PSPatricia Le Saëc
Patricia Le Saëc
AFAlain Faivre-Chauvet
Alain Faivre-Chauvet
1C1m-Fc, a promising anti-TEM-1 DOTA conjugate, was labeled with 64Cu to target cancer cells for PET imaging and predicting the efficacy and safety of a previously studied [177Lu]Lu-1C1m-Fc companion therapy. DOTA-conjugated 1C1m-Fc was characterized by mass spectrometry, thin layer chromatography and immunoreactivity assessment. PET/CT and biodistribution studies were performed in human neuroblastoma xenografted mice. Absorbed doses were assessed from biodistribution results and extrapolated to 177Lu based on the [64Cu]Cu-1C1m-Fc data. The immunoreactivity was ≥ 70% after 48 h of incubation in serum, and the specificity of [64Cu]Cu-1C1m-Fc for the target was validated. High-resolution PET/CT images were obtained, with the best tumor-to-organ ratios reached at 24 or 48 h and correlated with results of the biodistribution study. Healthy organs receiving the highest doses were the liver, the kidneys and the uterus. [64Cu]Cu-1C1m-Fc could be of interest to give an indication of 177Lu dosimetry for parenchymal organs. In the uterus and the tumor, characterized by specific TEM-1 expression, the 177Lu-extrapolated absorbed doses are overestimated because of the lack of later measurement time points. Nevertheless, 1C1m-Fc radiolabeled with 64Cu for imaging would appear as an interesting radionuclide companion for therapeutic application with [177Lu]Lu-1C1m-Fc.

14 June 2023 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
SGSilvano Gnesin
Silvano Gnesin
NCNicolas Chouin
Nicolas Chouin
MCMichel Chérel
Michel Chérel
SDSteven Mark Dunn
Steven Mark Dunn
NSNiklaus Schaefer
Niklaus Schaefer
judith delagejudith delage
judith delage
The development of diagnostic and therapeutic radiopharmaceuticals is an hot topic in nuclear medicine. Several radiolabeled antibodies are under development necessitating both biokinetic and dosimetry extrapolations for effective human translation. The validation of different animal-to-human dosimetry extrapolation methods still is an open issue. This study reports the mice-to-human dosimetry extrapolation of 64Cu/177Lu 1C1m-Fc anti-TEM-1 for theranostic application in soft-tissue sarcomas. We adopt four methods; direct mice-to-human extrapolation (M1); dosimetry extrapolation considering a relative mass scaling factor (M2), application of a metabolic scaling factor (M3) and combination of M2 and M3 (M4). Predicted in-human dosimetry for the [64Cu]Cu-1C1m-Fc resulted in an effective dose of 0.05 mSv/MBq. Absorbed dose (AD) extrapolation for the [177Lu]Lu-1C1m-Fc indicated that the AD of 2 Gy and 4 Gy to the red-marrow and total-body can be reached with 5–10 GBq and 25–30 GBq of therapeutic activity administration respectively depending on applied dosimetry method. Dosimetry extrapolation methods provided significantly different absorbed doses in organs. Dosimetry properties for the [64Cu]Cu-1C1m-Fc are suitable for a diagnostic in-human use. The therapeutic application of [177Lu]Lu-1C1m-Fc presents challenges and would benefit from further assessments in animals’ models such as dogs before moving into the clinic.

7 April 2026 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
CKChristel Hermann Kamani
Christel Hermann Kamani
JCJulien Costes
Julien Costes
MPMaxime Panchaud
Maxime Panchaud
KCKilian Casagrande
Kilian Casagrande
Giorgio TregliaGiorgio Treglia
Giorgio Treglia
John PriorJohn Prior
John Prior
Labelling WBC with [18F]FDG may be an alternative for accurate infection diagnosis, combining the excellent sensitivity of [18F]FDG with the excellent spec

5 May 2020 in Research Square
Verified
Preprint
Open access
PDF file
SDSteve Durante
Steve Durante
Vincent DunetVincent Dunet
Vincent Dunet
FGFrançois Gorostidi
François Gorostidi
PMPeriklis Mitsakis
Periklis Mitsakis
NSNiklaus Schaefer
Niklaus Schaefer
JPJohn O. Prior
John O. Prior
Background : Angiogenesis plays an important role in head and neck squamous cell carcinomas (HNSCC) progression. This pilot study was designed to compare the distribution of 68 Ga-NODAGA-RGD PET/CT for imaging α v β 3 integrins involved in tumor angiogenesis to 18 F-FDG PET/CT in patients with HNSCC. Material and methods : Ten patients (aged: 58.4 ± 8.3 years [range: 44–73 years], 6 males, 4 females) with a total of 11 HNSCC were prospectively enrolled. Activity mapping and standard uptake values (SUV) from both 68 Ga -NODAGA-RGD and 18 F-FDG PET/CT scans were recorded for primary tumor and compared with the Wilcoxon signed-rank test. The relation between the SUV of both tracers was assessed using the Spearman correlation. Results : All HNSCC tumors were visible with both tracers. Quantitative analysis showed higher 18 F-FDG SUV max in comparison to 68 Ga-NODAGA-RGD (14.0 ± 6.1 versus 3.9 ± 1.1 g/mL, p=0.0017) and SUV mean (8.2 ± 3.1 versus 2.0 ± 0.8 g/mL, p=0.0017). Both 18 F-FDG and 68 Ga-NODAGA-RGD uptake were neither correlated with grade, HPV nor p16 protein expression (p≥0.17). Conclusion : All HNSCC tumors were detected with both tracers with higher uptake with 18 F-FDG, however. 68 Ga-NODAGA-RGD has a different spatial distribution than 18 F-FDG bringing different tumor information.